We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Immunicon (MM) | NASDAQ:IMMC | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.19 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): February 29, 2008
IMMUNICON CORPORATION
(Exact Name of Registrant Specified in Charter)
Delaware | 000-50677 | 23-2269490 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
3401 Masons Mill Road, Suite 100 Huntingdon Valley, Pennsylvania |
19006 | |
(Address of Principal Executive Offices) | (Zip Code) |
Registrants telephone number, including area code: (215) 830-0777
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions ( see General Instruction A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Departure of Senior Vice President, Finance and Administration and Chief Financial Officer
On February 29, 2008, James G. Murphy tendered his resignation to the Board of Directors of Immunicon Corporation (Immunicon), pursuant to which Mr. Murphy resigned his current position as Immunicons Senior Vice President, Finance and Administration and Chief Financial Officer. Mr. Murphys resignation will be effective on March 14, 2008.
Mr. Murphys resignation is not as a result of any disagreement with Immunicon on any matter relating to Immunicons operations, policies or practices and Mr. Murphy will work closely with Immunicons management to ensure a smooth transition.
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, Immunicon has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IMMUNICON CORPORATION | ||
By: |
/s/ BYRON D. HEWETT |
|
Byron D. Hewett | ||
President and Chief Executive Officer | ||
Dated: March 6, 2008
1 Year Immunicon Chart |
1 Month Immunicon Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions